Abdominal wall

Urethral sounding: why some people find it pleasurable to insert objects into their urinary tube

Retrieved on: 
Wednesday, March 13, 2024
Lubrication, Woman, Penis, Blood, Urethra, Needle, Bladder cancer, Pain, Infection, Prostate, Pleasure, Erectile dysfunction, Risk, Trauma, Sleep paralysis, Psychogenic, Arousal, Clitoris, Urine, Male, Movement, Vertically transmitted infection, Nerve, Cystoscopy, Abdominal wall, Birth control

In case you’re wondering, the human urethra is a tube that carries urine from the bladder to outside the body.

Key Points: 
  • In case you’re wondering, the human urethra is a tube that carries urine from the bladder to outside the body.
  • Some people find it sexually pleasurable to insert objects – known as sounds, which are typically small glass or metal rods – or even fluid into the urethra.
  • Many objects have been used for sounding, however, and that’s one of the reasons the practice is so hazardous.
  • The urethra is a narrow outflow tube, usually less than 9mm wide, so squeezing objects into it isn’t usually recommended.
  • Megalouretha can lead to retention of objects in the urethra or bladder from clinical examinations such as cervical screening.

Risky business

  • It takes several turns to pass through the pelvic floor muscles, prostate and then, if inserted far enough, the bladder.
  • Urethral damage exposes the underlying connective tissues which can cause blood in the urine, as well as erectile dysfunction and even bladder rupture.
  • Trauma and damage may lead to further narrowing of the urethra in later life which may require medical intervention.

Sounds painful

  • But sounding can be highly sexually gratifying for some people.
  • The arousal and subsequent stimulation of the erectile tissue of the penis and clitoris usually occurs through one of two mechanisms: psychogenic (images or thoughts) or reflexogenic (touching).
  • The reflexogenic pathway is served by nerves which also innervate the lining of the urethra – the dorsal nerve(s) of the penis or clitoris.


Adam Taylor does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

IceCure's ProSense® a Promising Alternative Treatment for Extra-Pelvis Endometriosis: Independent Study Presented at ECR 2024

Retrieved on: 
Monday, March 4, 2024
Woman, PAIN, Neoplasm, Teaching hospital, Patient satisfaction, Abdominal wall, Endometriosis, Freezing, Visual analogue scale, Safety, Patient, MRI, Medical imaging

Five doctors participated in the study, including interventional radiologist and ProSense® user Prof. Julien Frandon, who has previously led hands-on training sessions with ProSense® at multiple medical conferences.

Key Points: 
  • Five doctors participated in the study, including interventional radiologist and ProSense® user Prof. Julien Frandon, who has previously led hands-on training sessions with ProSense® at multiple medical conferences.
  • The investigator-initiated single-site study enrolled 7 women, ages 30-45 years, with endometriosis in the abdominal wall and para-diaphragmatic areas.
  • One month following treatment, assessment by MRI revealed hemorrhagic signal had disappeared and necrotic changes developed.
  • We are very pleased that all patients treated in this study were relieved of their endometriosis condition and pain within as little as a month following treatment," stated IceCure CEO Eyal Shamir.

AbSolutions Med, Inc. Receives FDA Breakthrough Device Designation for its REBUILD™ Bioabsorbable Abdominal Wall Closure Device

Retrieved on: 
Thursday, January 25, 2024
Patient, Incisional hernia, General surgery, Abdominal wall, Medicine, Risk, Quality of life, Disease, Food, FDA, Three-body problem, Laparotomy

MOUNTAIN VIEW, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- AbSolutions Med, Inc., a privately held medical device company, announced today that the Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its REBUILD Bioabsorbable (“REBUILD”) abdominal wall closure device.

Key Points: 
  • MOUNTAIN VIEW, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- AbSolutions Med, Inc., a privately held medical device company, announced today that the Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its REBUILD Bioabsorbable (“REBUILD”) abdominal wall closure device.
  • REBUILD met the criteria set by the FDA for Breakthrough Devices, potentially providing a novel treatment of an often irreversibly debilitating condition: incisional hernia.
  • Since the first documented laparotomy in 1809, general surgery has been challenged by its limitations in reliably managing a basic but fundamental aspect of abdominal surgery – closure of the abdominal wall.
  • The impact of a failed abdominal closure can be devastating, with lifelong debilitation, morbidity, and re-operation occurring in a large percentage of patients.

Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors

Retrieved on: 
Monday, November 6, 2023
Aggressive fibromatosis, FDA, Organ dysfunction, Incidence, Food, Chronic pain, OTCQX, DT, Head, Plantar fibromatosis, Quality of life, Abdominal wall, Medicine, Patient, Food and Drug Administration, Diagnosis, GSI, Plasma protein binding, Pharmaceutical industry

REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to AL102, a Gamma Secretase Inhibitor (GSI), for the treatment of desmoid tumors (DT).

Key Points: 
  • REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to AL102, a Gamma Secretase Inhibitor (GSI), for the treatment of desmoid tumors (DT).
  • Orphan drug designation is granted by the FDA to drugs and biologics intended for treatment, prevention or diagnosis of a rare disease or condition that affects fewer than 200,000 people in the U.S. at the time of designation.
  • Under the FDA’s Orphan Drug Act, orphan drug status provides incentives, including tax credits, grants and waiver of certain administrative fees for clinical trials, and seven years of market exclusivity following drug approval.
  • “Receiving FDA orphan drug status for AL102 underscores the significant unmet need for novel treatment options for people living with desmoid tumors.

Why it's bad to always suck your stomach in

Retrieved on: 
Monday, July 31, 2023
People, Exercise, Yoga, Pressure, Human, Atmosphere, Lung, Urine, Oxygen, Uterine prolapse, Diaphragm, Spine, Research, Abdominal cavity, Neck, Pelvic floor, Uterus, Abdominal pain, Gastroschisis, Stomach, Abdomen, Pain, Rectum, Hourglass, Joint, Liver, Pelvic floor dysfunction, Abdominal wall, Pig, Medical imaging, Dietary supplement

But certain health conditions and even unnecessarily tensing the muscles during your daily life can cause the abdominal muscles to become imbalanced.

Key Points: 
  • But certain health conditions and even unnecessarily tensing the muscles during your daily life can cause the abdominal muscles to become imbalanced.
  • All of them result in an imbalance in the function of the abdominal muscles.
  • People who may feel insecure in their body or who want a flat stomach may suck their stomach muscles to achieve this look.

Muscle imbalance

    • This creates a fold or crease in the abdomen over a long period, with the belly button being pulled upwards.
    • Regardless of the cause – whether voluntary or involuntary – sucking the stomach in places greater pressure on the lower back and neck.
    • The pressure at the top affects breathing by making the diaphragm (the major muscle involved in drawing air in) unable to pull down as far.
    • Treating the muscular imbalance through exercises that strengthen all of the core muscles will help.
    • If you have unexplained or prolonged abdominal pain, it’s worth seeking medical advice – not only to prevent muscle imbalances but also to treat the root cause of the pain.

Advanced Robotic and Foregut Surgery Expert to Lead NYU Langone's Division of General Surgery

Retrieved on: 
Thursday, February 23, 2023
Medicine, Therapy, American College, Society, Loyola University, Molecular biology, NYU, Quality of life, University, Long Island University, Stomach, Gallstone, Empowerment, Staten Island University Hospital, Gastroenterology, NYU Langone Health, Patient, Foregut, Surgeon, Division, Faculty, New York University Grossman School of Medicine, Hernia, Health, Gender, Gastrointestinal tract, Abdominal wall, Woman, General surgery, Doctor of Philosophy, Dentistry, MD

NEW YORK, Feb. 23, 2023 /PRNewswire/ -- Tanuja Damani, MD , a nationally renowned expert in the fields of advanced robotic and foregut surgery, has been named the new chief of the Division of General Surgery at NYU Langone Health.

Key Points: 
  • NEW YORK, Feb. 23, 2023 /PRNewswire/ -- Tanuja Damani, MD , a nationally renowned expert in the fields of advanced robotic and foregut surgery, has been named the new chief of the Division of General Surgery at NYU Langone Health.
  • Dr. Damani currently serves as the section chief of esophageal and foregut surgery and recently launched the institution's inaugural minimally invasive and robotic surgery fellowship.
  • "I am humbled to work alongside and lead the incredibly talented faculty within the Division of General Surgery.
  • Dr. Damani travels nationally to train surgeons in robotic and foregut surgery and regularly presents at major national society meetings.

Intera 3000, the Only FDA-Approved Implantable Pump for HAI Therapy, Showcased at ASCO Gastrointestinal Cancer Symposium 2023

Retrieved on: 
Thursday, January 19, 2023
Oncology, Health, FDA, Medical Devices, Research, Science, Biotechnology, U.S. News & World Report, Toxicity, Neoplasm, Colorectal cancer, Abdominal wall, Moscone Center, Gastrointestinal cancer, Patient, Cholangiocarcinoma, Liver, Recurrence, Physician, HAI, Pharmaceutical industry, Medical imaging, FK Interas Visaginas

Intera Oncology® Inc. , the manufacturer of the only FDA-approved implantable pump used for hepatic artery infusion (HAI) therapy, will showcase its Intera 3000 HAI Pump at the 2023 ASCO Gastrointestinal Cancer Symposium , taking place at the Moscone West in San Francisco, Calif. from January 19 to 20, 2023.

Key Points: 
  • Intera Oncology® Inc. , the manufacturer of the only FDA-approved implantable pump used for hepatic artery infusion (HAI) therapy, will showcase its Intera 3000 HAI Pump at the 2023 ASCO Gastrointestinal Cancer Symposium , taking place at the Moscone West in San Francisco, Calif. from January 19 to 20, 2023.
  • HAI therapy is a powerful treatment option for colorectal cancer that has spread to the liver and for intrahepatic cholangiocarcinoma.
  • Recently published clinical studies demonstrate the potential of HAI therapy to improve survival rates, increase conversion to resection and reduce the frequency of recurrence.
  • “Our pump is an important treatment option in the advanced cancer care space where patients and physicians need better treatment options,” said president and CEO of Intera Oncology, Michael Gaisford.

Corvus Pharmaceuticals Presents Updated Data from CPI-818 (ITK Inhibitor) Phase 1/1b Clinical Trial at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition

Retrieved on: 
Monday, December 12, 2022
Immunotherapy, Lymphoma, B-cell lymphoma, T helper 17 cell, Head, Cutaneous T cell lymphoma, Clinical trial, PD, Incidence, Partnership, Atopic dermatitis, Prevalence, SD, Neoplasm, Poster, Safety, ITK, Pharmacokinetics, TCL, Toxic epidermal necrolysis, Large-cell lung carcinoma, ASH, Exposition, Neck, CR, T-cell lymphoma, Patient, PTCL, Autoimmunity, Research, Plasma, Society, PR, Abdominal wall, PRS, Vaccine, Pharmaceutical industry, Palladium, T helper cell, Corvus, TH1

BURLINGAME, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced updated results from its Phase 1/1b trial of CPI-818, the Company’s ITK inhibitor, which demonstrated its anti-tumor activity in patients with T cell lymphoma (TCL) and its therapeutic potential in Th2 and Th17-mediated autoimmune and allergic diseases. The data will be presented today in a poster at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition, which is taking place in-person and virtually from December 10 to 13, 2022.

Key Points: 
  • The data will be presented today in a poster at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition, which is taking place in-person and virtually from December 10 to 13, 2022.
  • Based on the clinical results to-date, we plan to advance CPI-818 into a global Phase 2 clinical trial in T cell lymphoma in mid-2023.
  • Accordingly, Corvus identified it as the optimal dose and additional patients are being enrolled in a 200 mg dose cohort of the clinical trial.
  • The Phase 1/1b clinical trial endpoints are safety, pharmacokinetics (PK), immunologic effects and tumor response.

Asensus Surgical Announces Ludwig Maximilians University in Germany to Initiate Senhance Pediatric Surgery Program

Retrieved on: 
Tuesday, November 8, 2022
GLOBE, Tremor, Filtration, Ludwig Maximilian University of Munich, Burns, NYSE, Accident, Elective surgery, Intelligence, Research, Health, Sale, Abdominal wall, Pediatric neurosurgery, Pectus excavatum, Thorax, Pediatric urology, Company, RESEARCH, PARK, Deep learning, Birth, Patient, Growth, CEO, Surgeon, Medical device, Dentistry, Medicine

We are very excited that the LMU University Hospital will be utilizing a Senhance System as part of their pediatric surgery department.

Key Points: 
  • We are very excited that the LMU University Hospital will be utilizing a Senhance System as part of their pediatric surgery department.
  • This is a significant milestone for Asensus as this represents the first Senhance program devoted entirely to pediatric procedures, said Anthony Fernando, Asensus Surgical President and CEO.
  • We look forward to partnering with the pediatric team at LMU University Hospital to transform the way they deliver care to their pediatric patients.
  • The platform will be a great asset to our hospital, and we are very excited to launch our Senhance pediatric surgical program.

TELA Bio Announces Publication of 24-Month BRAVO Study Results Demonstrating Benefits of OviTex® Reinforced Tissue Matrix in Hernia Repair

Retrieved on: 
Wednesday, October 26, 2022
Hernia, Company, 1S, Security (finance), CDC, U.S. Securities and Exchange Commission, Weakness, NASDAQ, Obesity, IceWall SSO, CEO, Recurrence, General surgery, Surgical mesh, Sheep, FACS, St. Francis Hospital, SSO, Annual report, Patient, Private Securities Litigation Reform Act, Risk, Quality of life, Research, GLOBE, Anatomy, Infection, Use, Coronary artery disease, Surgeon, BRAVO, COPD, Abdominal wall, Diabetes, Dentistry, Pharmaceutical industry, Medical device, Medical imaging, MD, Medicine

Our results provide evidence that OviTex 1S Permanent in ventral hernia repair results in a low rate of recurrence and improved quality of life for patients over a two-year period.

Key Points: 
  • Our results provide evidence that OviTex 1S Permanent in ventral hernia repair results in a low rate of recurrence and improved quality of life for patients over a two-year period.
  • We are very proud to share the full, final results of our BRAVO study, stated Antony Koblish, President and CEO of TELA Bio.
  • This commitment continues with our ongoing BRAVO II study which will evaluate the use of OviTex in robot-assisted ventral and inguinal hernia repairs.
  • OviTex Reinforced Tissue Matrix is intended for use as a surgical mesh to reinforce and/or repair soft tissue where weakness exists.